F₃CCHBrCl

1-bromo-1-chloro-2,2,2-trifluoroethane; 2-bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-trifluoro-2-bromo-2-chloroethane; 2,2,2-trifluoro-1-bromo-1-chloroethane

50 ppm [1979]

2 ppm (16 mg/m³)

2 ppm (16.2 mg/m³) [60 minutes]

NA

N

N

N

Not established

REL IS FOR EXPOSURE TO WASTE ANESTHETIC GASES

NOAA: CAMEO Chemicals - Halothane

NIOSH: Pocket Guide to Chemical Hazards - Halothane

Literature References

• ACGIH: Documentation of the Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) - Halothane. See annual publication for most recent information.
• Imbriani, M., Ghittori, S., Zadra, P. and Imberti, R.: Biological monitoring of the occupational exposure to halothane (fluothane) in operating room personnel. Am. J. Ind. Med. 20(1): 103-112, 1991.
• Kenna, J.G., Satoh, H., Christ, D.D. and Pohl, L.R.: Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245(3): 1103-1109, 1988.
• Njoku, D.B., et al.: Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg. 94(2): 243-249, 2002.
• Pohanish, R.P. (editor): Halothane. In, Sittig’s Handbook of Toxic and Hazardous Chemicals and Carcinogens, Fourth Ed., Vol. 1. Norwich, NY: Noyes Publications, William Andrew Publishing, 2002, pp. 1221-1223.
• Sutherland, D.E. and Smith, W.A.: Chemical hepatitis associated with occupational exposure to halothane in a research laboratory. Vet. Hum. Toxicol. 34(5): 423-424, 1992.